Risk of MS relapse and deterioration after COVID-19: A systematic review and meta-analysis

Homa Seyedmirzaei, Dorsa Salabat, Sara KamaliZonouzi, Antônio L. Teixeira, Nima Rezaei

Producción científica: Review articlerevisión exhaustiva

2 Citas (Scopus)

Resumen

Background: Upper respiratory viral infections have long been considered triggers for multiple sclerosis (MS) relapse and exacerbation. The possible effects of SARS-CoV-2 infection on MS relapse and deterioration remain controversial. Methods: We systematically searched PubMed, Scopus, Embase, Cochrane, and Web of Science databases to find relevant studies assessing changes in relapse rates or Expanded Disability Status Scale (EDSS) following COVID-19 in people with MS. Meta-analyses were performed, and to investigate sources of heterogeneity, subgroup analysis, meta-regression, and sensitivity analysis were conducted. Results: We included 14 studies in our systematic review and meta-analysis. The meta-analysis demonstrated that COVID-19 was not associated with a rise in relapse rate (risk ratio (RR): 0.97, 95 % confidence interval (CI): 0.67, 1.41, p-value: 0.87) or a rise in EDSS (standardized mean difference (SMD): −0.09, 95 % CI: −0.22, 0.03, p-value: 0.13). The analysis of EDSS changes indicated a significant heterogeneity (I2: 55 %, p-value: 0.01). Other analyses were not statistically significant. Conclusions: COVID-19 infection was not associated with an increased risk of relapse and clinical deterioration in people with MS.

Idioma originalEnglish (US)
Número de artículo105472
PublicaciónMultiple Sclerosis and Related Disorders
Volumen83
DOI
EstadoPublished - mar 2024
Publicado de forma externa

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Huella

Profundice en los temas de investigación de 'Risk of MS relapse and deterioration after COVID-19: A systematic review and meta-analysis'. En conjunto forman una huella única.

Citar esto